INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces it participation to major upcoming medical meetings

Transparency directive : regulatory news

03/06/2010 18:47

Press release

  INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO MAJOR UPCOMING MEDICAL MEETINGS

Marseilles, France, June 3, 2010

Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces today that it will
report clinical data for its two lead clinical drug candidate at the following
June's medical meetings:

- At the Annual European Hematology Association ("EHA") Meeting, in Barcelona,
  Spain, on June 13, 2010:

  Final data from the Phase I/II clinical trial evaluating IPH 1101 in
  combination with rituximab in follicular non-Hodgkin's lymphoma ("fNHL")
  patients (study "IPH 1101-202") will be subject to an oral presentation by
  Pr Jean-François Rossi (Head of Hemato-Oncology Department and Center of
  Clinical Investigation BT 509, University Hospital, Montpellier, France),
  co-lead investigator of the study (Abstract 1131, A phase I/II study of
  IPH1101, gamma delta T cell agonist, in combination with rituximab
  re-treatment, in patients with low grade follicular lymphoma).

  Innate Pharma management will host a conference call to discuss these results
  on June 14, 2010. More details to connect to this conference call will be
  provided in the press release reporting the results and on the website.

- At the Annual American Society of Clinical Oncology ("ASCO") Meeting on
  June 5, 2010:

  Updated interim data for the Phase I trial with IPH 2101 in Multiple Myeloma
  patients (study "IPH 2101-103"). The interim results will be subject to a
  poster presented by Don Benson, MD, PhD (Division of Hematology/Oncology,
  Ohio State Cancer Center, Columbus, OH), during the Lymphoma and Plasma Cell
  Disorders session (Abstract 8139, A phase I study of IPH2101, a novel
  anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma).

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company has two drug candidates currently in Phase II clinical trials. Two of
its preclinical programs are out-licensed to Novo Nordisk A/S.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006,
Innate Pharma is based in Marseilles, France, and had 79 employees as at
March 30, 2010.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus,
which is available on the AMF website (http://www.amffrance.org) or on Innate
Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                       Alize Public Relations
Laure-Hélène Mercier                Caroline Carmagnol
Director, Investor Relations        Phone: +33 (0) 1 42 68 86 43
Phone: +33 (0)4 30 30 30 87         Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com         caroline@alizerp.com

IPH next medical meetings

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces it participation to major upcoming medical meetings

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories